PSEN2 and Alzheimer disease: Over an observation period of 3 years among carriers of AD‐causing mutations in APP, PSEN1, or PSEN2, we found that higher levels of soluble Aβ42 predicted a lower risk of cognitive impairment to a greater extent than lower levels of brain amyloid [26].